Mereo BioPharma and Sentynl sign option deal for alvelestat in lung disease
Sentynl gets an option for U.S. rights to Mereo's alvelestat, with milestone payments up to $435 million if the option is exercised.
SEC filing
Latest
2 stories
Tuesday, August 11
Tuesday, August 4
Ultragenyx reports Q2 2026 results, cites two PDUFA dates and Angelman readout ahead
The company reaffirmed full-year 2026 revenue guidance and flagged upcoming FDA decisions for DTX401 and UX111 alongside pivotal Phase 3 data for GTX-102 in Angelman syndrome.
SEC filing